TY - JOUR
T1 - Subcutaneous Adipose Tissue Metabolic Function and Insulin Sensitivity in People With Obesity
AU - Koh, Han Chow E.
AU - van Vliet, Stephan
AU - Pietka, Terri A.
AU - Meyer, Gretchen A.
AU - Razani, Babak
AU - Laforest, Richard
AU - Gropler, Robert J.
AU - Mittendorfer, Bettina
N1 - Funding Information:
Acknowledgments. The authors thank the staff of the Center for Human Nutrition, the Clinical Translational Research Unit, the Clinical Translational Imaging Unit, and the Division of Radiological Sciences for help with participant recruitment, scheduling, and testing and technical assistance with sample processing and data analysis, and the study participants for their time and commitment. Funding. The work presented in this manuscript was supported by National Institutes of Health grants R01 DK115400, P30 DK56341 (Nutrition Obesity Research Center), P30 DK020579 (Diabetes Research Center), P30 DK052574 (Digestive Disease Research Core Center), and UL1TR000448 (Clinical Translational Science Award) and grants from the American Diabetes Association (1-18-ICTS-119) and the Longer Life Foundation. Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. R.J.G. and B.M. designed the study. H.-C.E.K., S.v.V., T.A.P., G.A.M., B.R., R.L., R.J.G., and B.M. contributed to data acquisition, data analysis, and data interpretation. H.-C.E.K. and B.M. wrote the first draft of the manuscript. All authors contributed to the revision of the manuscript for crucial intellectual content and approved the final manuscript for publication. B.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Publisher Copyright:
© 2021, American Diabetes Association Inc. All rights reserved.
PY - 2021/10
Y1 - 2021/10
N2 - We used stable isotope–labeled glucose and palmitate tracer infusions, a hyperinsulinemic-euglycemic clamp, positron emission tomography of muscles and adipose tissue after [18F]fluorodeoxyglucose and [15O]water injections, and subcutaneous adipose tissue (SAT) biopsy to test the hypotheses that 1) increased glucose uptake in SAT is responsible for high insulin-stimulated whole-body glucose uptake in people with obesity who are insulin sensitive and 2) putative SAT factors thought to cause insulin resistance are present in people with obesity who are insulin resistant but not in those who are insulin sensitive. We found that high insulin-stimulated whole-body glucose uptake in insulin-sensitive participants with obesity was not due to channeling of glucose into SAT but, rather, was due to high insulin-stimulated muscle glucose uptake. Furthermore, insulin-stimu-lated muscle glucose uptake was not different between insulin-sensitive obese and lean participants even though adipocytes were larger, SAT perfusion and oxygenation were lower, and markers of SAT inflammation, fatty acid appearance in plasma in relation to fat-free mass, and plasma fatty acid concentration were higher in the insulin-sensitive obese than in lean participants. In addition, we observed only marginal or no differences in adipocyte size, SAT perfusion and oxygenation, and markers of SAT inflammation between insulin-resistant and insulin-sensitive obese participants. Plasma fatty acid concentration was also not different between insulin-sensitive and insulin-resistant obese participants, even though SAT was resistant to the inhibitory effect of insulin on lipolysis in the insulin-resistant obese group. These data suggest that several putative SAT factors commonly implicated in causing insulin resistance are normal consequences of SAT expansion unrelated to insulin resistance.
AB - We used stable isotope–labeled glucose and palmitate tracer infusions, a hyperinsulinemic-euglycemic clamp, positron emission tomography of muscles and adipose tissue after [18F]fluorodeoxyglucose and [15O]water injections, and subcutaneous adipose tissue (SAT) biopsy to test the hypotheses that 1) increased glucose uptake in SAT is responsible for high insulin-stimulated whole-body glucose uptake in people with obesity who are insulin sensitive and 2) putative SAT factors thought to cause insulin resistance are present in people with obesity who are insulin resistant but not in those who are insulin sensitive. We found that high insulin-stimulated whole-body glucose uptake in insulin-sensitive participants with obesity was not due to channeling of glucose into SAT but, rather, was due to high insulin-stimulated muscle glucose uptake. Furthermore, insulin-stimu-lated muscle glucose uptake was not different between insulin-sensitive obese and lean participants even though adipocytes were larger, SAT perfusion and oxygenation were lower, and markers of SAT inflammation, fatty acid appearance in plasma in relation to fat-free mass, and plasma fatty acid concentration were higher in the insulin-sensitive obese than in lean participants. In addition, we observed only marginal or no differences in adipocyte size, SAT perfusion and oxygenation, and markers of SAT inflammation between insulin-resistant and insulin-sensitive obese participants. Plasma fatty acid concentration was also not different between insulin-sensitive and insulin-resistant obese participants, even though SAT was resistant to the inhibitory effect of insulin on lipolysis in the insulin-resistant obese group. These data suggest that several putative SAT factors commonly implicated in causing insulin resistance are normal consequences of SAT expansion unrelated to insulin resistance.
UR - http://www.scopus.com/inward/record.url?scp=85117878247&partnerID=8YFLogxK
U2 - 10.2337/DB21-0160
DO - 10.2337/DB21-0160
M3 - Article
C2 - 34266892
AN - SCOPUS:85117878247
SN - 0012-1797
VL - 70
SP - 2225
EP - 2236
JO - Diabetes
JF - Diabetes
IS - 10
ER -